Biotech Archives - Page 85 of 795

2 minute read

Metabolic Diseases-Focused Eiger BioPharmaceuticals Files For Bankruptcy, Stock Nosedives

April 1, 1:43 PM

Eiger BioPharmaceuticals files for Chapter 11 bankruptcy protection. Plans to sell Zokinvy (lonafarnib) to Sentynl Therapeutics or up to $26.0 million. Potential bidders can submit competing bids.

EIGR

1 minute read

Why Is Regenerative Medicine-Focused Surrozen Stock Trading Lower On Monday?

By Vandana Singh

April 1, 1:14 PM

Surrozen engages in a private placement, aiming to raise approximately $192.5 million in gross proceeds. Updates on SZN-043 Phase 1a trial reveal promising safety, tolerability, and effects on liver function.

SRZN

2 minute read

Micro-Cap Cancer Focused Candel Therapeutics Highlights Encouraging Data From Brain Tumor Immunotherapy

By Vandana Singh

April 1, 12:49 PM

Data from Candel Therapeutics on CAN-3110, a promising viral immunotherapy for recurrent high-grade glioma. Discover survival rates and potential advancements in cancer treatment.

CADL

2 minute read

Medical Devices Giant Baxter Secures FDA Approval For New Infusion Pump System

By Vandana Singh

April 1, 12:38 PM

FDA clears Baxter's Novum IQ LVP & SYR infusion pumps with Dose IQ Safety Software, streamlining training & reducing cognitive burden. Explore enhanced safety features & EMR interoperability.

BAX

2 minute read

FDA Presses Delay Button For Applied Therapeutics’ First Potential Marketed Drug For Rare Disease

By Vandana Singh

April 1, 12:30 PM

FDA extends the review period for Applied Therapeutics' NDA for govorestat, targeting Classic Galactosemia treatment. The new action date is set for November 28, 2024. Applied Therapeutics anticipates a decision from EMA in Q4 2024.

APLT

3 minute read

Reported Earlier, Vertex Advances Inaxaplin Into Phase 3 Portion Of Adaptive Phase 2/3 Clinical Trial For The Treatment Of APOL1-Mediated Kidney Disease

By Benzinga Newsdesk

April 1, 11:02 AM

– 45 mg once daily oral dose selected for Phase 3 –– Results support trial expansion to lower age group and study will now include adolescents ages 10-17 years –– If positive, pre-planned interim analysis at Week 48 may

VRTX

1 minute read

Vertex Announces New Drug Submission For Exagamglogene Autotemcel Has Been Accepted For Priority Review By Health Canada For The Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia

By Benzinga Newsdesk

April 1, 11:01 AM

-Exa-cel is the first CRISPR-based gene-edited therapy to be submitted for Health Canada review-TORONTO, April 1, 2024 /CNW/ - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced its New Drug

VRTX

2 minute read

Disc Medicine Stock Plunges As Light Sensitivity Treatment Data Confounded Due To Outsized Placebo Response

By Vandana Singh

April 1, 10:52 AM

Disc Medicine releases AURORA Phase 2 study data on bitopertin for Erythropoietic Protoporphyria. Significant reductions in PPIX levels and improvements in phototoxic reactions observed with bitopertin treatment.

DISC

2 minute read

One Good, One Bad News For Bristol Myers Squibb’s Marketed Drugs: Details

By Vandana Singh

April 1, 9:44 AM

Bristol Myers Squibb shares update on Phase 3 YELLOWSTONE trial for Zeposia (ozanimod) in Crohn's disease. Primary endpoint not met, safety consistent. Also, positive Phase 3 results for Krazati (adagrasib) in KRASG12C-mutated NSCLC.

BMY

1 minute read

Cyclacel Pharmaceuticals To Present New Clinical Data At 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential As A Precision Medicine For Cancer

By Benzinga Newsdesk

April 1, 9:16 AM

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma -BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE

CYCC